Xponance Inc. Buys 216 Shares of Penumbra, Inc. (NYSE:PEN)

Xponance Inc. grew its holdings in shares of Penumbra, Inc. (NYSE:PEN) by 2.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,948 shares of the company’s stock after buying an additional 216 shares during the period. Xponance Inc.’s holdings in Penumbra were worth $1,887,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of PEN. True Wealth Design LLC bought a new position in shares of Penumbra during the 3rd quarter worth approximately $26,000. UMB Bank n.a. boosted its holdings in shares of Penumbra by 57.4% during the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $46,000 after buying an additional 70 shares in the last quarter. Mather Group LLC. boosted its holdings in shares of Penumbra by 208.0% during the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after buying an additional 208 shares in the last quarter. Advisors Asset Management Inc. raised its position in shares of Penumbra by 11.5% during the third quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock worth $81,000 after purchasing an additional 43 shares during the period. Finally, Jones Financial Companies Lllp raised its position in shares of Penumbra by 25.0% during the fourth quarter. Jones Financial Companies Lllp now owns 375 shares of the company’s stock worth $89,000 after purchasing an additional 75 shares during the period. 88.88% of the stock is currently owned by institutional investors.

Insider Transactions at Penumbra

In other Penumbra news, Director Harpreet Grewal sold 167 shares of the firm’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $241.28, for a total value of $40,293.76. Following the completion of the transaction, the director now owns 8,530 shares in the company, valued at $2,058,118.40. This trade represents a 1.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Adam Elsesser sold 16,600 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $276.21, for a total value of $4,585,086.00. Following the completion of the transaction, the chief executive officer now owns 27,752 shares of the company’s stock, valued at approximately $7,665,379.92. This represents a 37.43 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 81,518 shares of company stock worth $22,994,979. 5.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

PEN has been the topic of a number of research reports. Wells Fargo & Company upped their target price on Penumbra from $275.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Bank of America initiated coverage on Penumbra in a research report on Friday, March 14th. They set a “buy” rating and a $320.00 target price on the stock. Oppenheimer initiated coverage on Penumbra in a research report on Tuesday, December 17th. They set an “outperform” rating and a $275.00 target price on the stock. Morgan Stanley upped their target price on Penumbra from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 19th. Finally, UBS Group upped their target price on Penumbra from $305.00 to $320.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $294.47.

Penumbra Trading Down 0.1 %

Shares of Penumbra stock opened at $280.93 on Friday. Penumbra, Inc. has a 1 year low of $148.00 and a 1 year high of $310.00. The firm has a market cap of $10.82 billion, a PE ratio of 826.25, a P/E/G ratio of 2.83 and a beta of 0.51. The stock has a fifty day moving average price of $272.70 and a 200-day moving average price of $240.30. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.09. The company had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. Equities research analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current year.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.